Idiopathic Pulmonary Fibrosis Clincal Research Network

The summary for the Idiopathic Pulmonary Fibrosis Clincal Research Network grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Idiopathic Pulmonary Fibrosis Clincal Research Network: The purpose of this initiative is to: 1) establish a Clinical Research Network (CRN) of 6 to 7 clinical centers to design and perform multiple therapeutic trials for treatment of patients with newly diagnosed idiopathic pulmonary fibrosis usual interstitial pneumonitis variety (termed IPF), and (2) establish a Data Coordinating Center for the network. This RFA is a one time solicitation to support these clinical centers and Data Coordinating Center for 5 years. This CRN will create the infrastructure for conducting multiple, collaborative therapeutic trials with relative speed and efficiency. These trials may evaluate existing or new medications, combinations of medications, and defined management strategies.

Federal Grant Title:	Idiopathic Pulmonary Fibrosis Clincal Research Network
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-04-021
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.838
CFDA Descriptions:	Lung Diseases Research
Current Application Deadline:	No deadline provided
Original Application Deadline:	Jun 21, 2004
Posted Date:	Mar 23, 2004
Creation Date:	Mar 23, 2004
Archive Date:	Oct 14, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • Limited Competition: Physician Scientist Transition to Independence in Blood Science Resea...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Data Coordi...; • Single Source: Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Human Tissu...; • Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clin...; • Pathogenesis of Sars Lung Disease: in Vitro Studies and Animal Models; • Lung Response to Inhaled Highly Toxic Chemicals; • Protein Interactions Governing Membrane Transport in Pulmonary Health and Disease (R01)
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...